Circular RNA as a New Vaccine Platform: Considerations, Challenges, and Perspectives

Area of Science:

• Biotechnology
• Immunology
• Molecular Biology

Background:

• Circular RNA (circRNA) presents a stable alternative to linear messenger RNA (mRNA) for vaccine development.
• The success of mRNA vaccines has spurred interest in circRNA platforms for prophylactic and cancer immunization.
• circRNA utilizes cap-independent translation and is produced via in vitro transcription with self-circularization.

Purpose of the Study:

• To review recent advancements in circRNA-based vaccine applications for prophylactic and cancer settings.
• To highlight in vitro transcription-compatible self-circularization strategies for circRNA production.
• To discuss how design, translation, purification, and delivery methods influence immunological outcomes.

Main Methods:

• Review of current literature on circRNA vaccine development and application.
• Analysis of self-circularization techniques for in vitro transcription-compatible circRNA synthesis.
• Examination of factors affecting circRNA vaccine efficacy, including design, translation, purification, and delivery.

Main Results:

• circRNA vaccines demonstrate sustained antigen presentation and elicit strong humoral and cellular immune responses.
• In prophylactic settings, circRNA supports germinal center reactions and neutralizing antibody generation.
• In cancer vaccines, circRNA effectively induces CD8+ T cell immunity and facilitates combination immunotherapy.

Conclusions:

• circRNA technology offers a promising platform for developing next-generation vaccines.
• Methodological choices in circRNA vaccine development significantly impact immunological effectiveness.
• Further research into circRNA design, production, and delivery will optimize its potential in vaccination.